Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects

Although the detailed pathogenesis of multiple sclerosis (MS) is not completely understood, a broad range of disease-modifying therapies (DMTs) are available. A common side effect of nearly every MS therapeutic agent is lymphopenia, which can be both beneficial and, in some cases, treatment-limiting...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stefanie Fischer, Undine Proschmann, Katja Akgün, Tjalf Ziemssen
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	multiple sclerosis lymphocyte counts mechanism of action adverse event Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/773e4e5edb1145db9fb77154980f8385
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:773e4e5edb1145db9fb77154980f8385
record_format	dspace
spelling	oai:doaj.org-article:773e4e5edb1145db9fb77154980f83852021-11-25T17:12:22ZLymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects10.3390/cells101131772073-4409https://doaj.org/article/773e4e5edb1145db9fb77154980f83852021-11-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/3177https://doaj.org/toc/2073-4409Although the detailed pathogenesis of multiple sclerosis (MS) is not completely understood, a broad range of disease-modifying therapies (DMTs) are available. A common side effect of nearly every MS therapeutic agent is lymphopenia, which can be both beneficial and, in some cases, treatment-limiting. A sound knowledge of the underlying mechanism of action of the selected agent is required in order to understand treatment-associated changes in white blood cell counts, as well as monitoring consequences. This review is a comprehensive summary of the currently available DMTs with regard to their effects on lymphocyte count. In the first part, we describe important general information about the role of lymphocytes in the course of MS and the essentials of lymphopenic states. In the second part, we introduce the different DMTs according to their underlying mechanism of action, summarizing recommendations for lymphocyte monitoring and definitions of lymphocyte thresholds for different therapeutic regimens.Stefanie FischerUndine ProschmannKatja AkgünTjalf ZiemssenMDPI AGarticlemultiple sclerosislymphocyte countsmechanism of actionadverse eventBiology (General)QH301-705.5ENCells, Vol 10, Iss 3177, p 3177 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	multiple sclerosis lymphocyte counts mechanism of action adverse event Biology (General) QH301-705.5
spellingShingle	multiple sclerosis lymphocyte counts mechanism of action adverse event Biology (General) QH301-705.5 Stefanie Fischer Undine Proschmann Katja Akgün Tjalf Ziemssen Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
description	Although the detailed pathogenesis of multiple sclerosis (MS) is not completely understood, a broad range of disease-modifying therapies (DMTs) are available. A common side effect of nearly every MS therapeutic agent is lymphopenia, which can be both beneficial and, in some cases, treatment-limiting. A sound knowledge of the underlying mechanism of action of the selected agent is required in order to understand treatment-associated changes in white blood cell counts, as well as monitoring consequences. This review is a comprehensive summary of the currently available DMTs with regard to their effects on lymphocyte count. In the first part, we describe important general information about the role of lymphocytes in the course of MS and the essentials of lymphopenic states. In the second part, we introduce the different DMTs according to their underlying mechanism of action, summarizing recommendations for lymphocyte monitoring and definitions of lymphocyte thresholds for different therapeutic regimens.
format	article
author	Stefanie Fischer Undine Proschmann Katja Akgün Tjalf Ziemssen
author_facet	Stefanie Fischer Undine Proschmann Katja Akgün Tjalf Ziemssen
author_sort	Stefanie Fischer
title	Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
title_short	Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
title_full	Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
title_fullStr	Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
title_full_unstemmed	Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
title_sort	lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/773e4e5edb1145db9fb77154980f8385
work_keys_str_mv	AT stefaniefischer lymphocytecountsandmultiplesclerosistherapeuticsbetweenmechanismsofactionandtreatmentlimitingsideeffects AT undineproschmann lymphocytecountsandmultiplesclerosistherapeuticsbetweenmechanismsofactionandtreatmentlimitingsideeffects AT katjaakgun lymphocytecountsandmultiplesclerosistherapeuticsbetweenmechanismsofactionandtreatmentlimitingsideeffects AT tjalfziemssen lymphocytecountsandmultiplesclerosistherapeuticsbetweenmechanismsofactionandtreatmentlimitingsideeffects
_version_	1718412656608542720

Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects

Ejemplares similares